Dexmedetomidine
Conditions
Brief summary
This study aims to evaluate the effect of dexmedetomidine on the level of agitation during the weaning process from mechanical ventilation in critically ill patients.
Interventions
DRUGGroup A (Dexmedetomidine Group)
patients will receive dexmedetomidine infusion starting at 0.2 mcg/kg/hr.
patients will receive standard ICU sedation protocol without dexmedetomidine (e.g., fentanyl)
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult ICU patients (≥18 years). * On mechanical ventilation ≥24 hours. * Clinically ready for weaning. * Agitation score RASS ≥ +1 during spontaneous breathing trial. * Intubation for at least 4 days: 2 weeks.
Exclusion criteria
* Known hypersensitivity to dexmedetomidine. * Hemodynamic instability (HR \< 50 bpm or MAP \< 60 mmHg). * Neurological impairment affecting level of consciousness. * Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of Dexmedetomidine on Agitation During Weaning from Mechanical Ventilation | every half an hour for two hours | Richmond Agitation-Sedation Scale |
Countries
Egypt
Contacts
Primary ContactDalia A Hussein, Resident
Backup ContactAl-haddad A Mousa, Professor
Outcome results
None listed